This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sagiv, E. Articles by Arber, N. Search for Related Content PubMed PubMed Citation Articles by Sagiv, E. Articles by Arber, N.

Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA

¹ The Integrated Cancer Prevention Center and ² Lung and Allergy Institute, Tel Aviv Medical Center; ³ The David and Inez Myers Laboratory for Genetic Research; ⁴ Department of Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv, Israel; ⁵ Tumor Immunology Programme, D010, German Cancer Research Center, Heidelberg, Germany; and ⁶ Columbia University, New York, New York

Requests for reprints: Nadir Arber, Integrated Cancer Prevention Center, Tel Aviv Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel. Phone: 972-3-697-4968; Fax: 972-3-695-0339; E-mail: narber{at}post.tau.ac.il.

Key Words: CD24 • monoclonal antibodies • siRNA • microarray • chemotherapy

CD24 is a potential oncogene reported to be overexpressed in a large variety of human malignancies. We have shown that CD24 is overexpressed in 90% of colorectal tumors at a fairly early stage in the multistep process of carcinogenesis. Anti-CD24 monoclonal antibodies (mAb) induce a significant growth inhibition in colorectal and pancreatic cancer cell lines that express the protein. This study is designed to investigate further the effects of CD24 down-regulation using mAb or small interfering RNA in vitro and in vivo. Western blot analysis showed that anti-CD24 mAb induced CD24 protein down-regulation through lysosomal degradation. mAb augmented growth inhibition in combination with five classic chemotherapies. Xenograft models in vivo showed that tumor growth was significantly reduced in mAb-treated mice. Similarly, stable growth inhibition of cancer cell lines was achieved by down-regulation of CD24 expression using short hairpin RNA (shRNA). The produced clones proliferated more slowly, reached lower saturation densities, and showed impaired motility. Most importantly, down-regulation of CD24 retarded tumorigenicity of human cancer cell lines in nude mice. Microarray analysis revealed a similar pattern of gene expression alterations when cells were subjected to anti-CD24 mAb or shRNA. Genes in the Ras pathway, mitogen-activated protein kinase, or BCL-2 family and others of oncogenic association were frequently down-regulated. As a putative new oncogene that is overexpressed in gastrointestinal malignancies early in the carcinogenesis process, CD24 is a potential target for early intervention in the prevention and treatment of cancer. [Cancer Res 2008;68(8):2803–12]

This article has been cited by other articles:

				C. Y. Chen, H. Kimura, M. A. Landek-Salgado, J. Hagedorn, M. Kimura, K. Suzuki, W. Westra, N. R. Rose, and P. Caturegli Regenerative Potentials of the Murine Thyroid in Experimental Autoimmune Thyroiditis: Role of CD24 Endocrinology, January 1, 2009; 150(1): 492 - 499. [Abstract] [Full Text] [PDF]

				G. Rappa, O. Fodstad, and A. Lorico The Stem Cell-Associated Antigen CD133 (Prominin-1) Is a Molecular Therapeutic Target for Metastatic Melanoma Stem Cells, December 1, 2008; 26(12): 3008 - 3017. [Abstract] [Full Text] [PDF]